Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

Meletios A. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesus San-Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špička, Adam Walter-Croneck, Hila Magen, Maria Victoria Mateos, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph RölligHermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C. Anderson, Ying Ming Jou, Alex Ganetsky, Anil K. Singhal, Paul G. Richardson显示 8 其他显示更少